Fulgent Genetics (NASDAQ:FLGT) Releases FY 2026 Earnings Guidance

Fulgent Genetics (NASDAQ:FLGT) updated its FY 2026 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of -1.590–1.590 for the period, compared to the consensus estimate of -1.590. The company issued revenue guidance of $350.0 million-$350.0 million, compared to the consensus revenue estimate of $349.4 million.

Wall Street Analyst Weigh In

FLGT has been the topic of a number of research reports. Zacks Research cut Fulgent Genetics from a “strong-buy” rating to a “hold” rating in a report on Monday, February 9th. Wall Street Zen lowered Fulgent Genetics from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Fulgent Genetics in a research note on Thursday, January 22nd. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $32.00.

Fulgent Genetics Price Performance

Shares of NASDAQ:FLGT opened at $15.19 on Friday. Fulgent Genetics has a 1 year low of $13.46 and a 1 year high of $31.04. The company has a market cap of $451.86 million, a P/E ratio of -7.75 and a beta of 0.89. The stock’s fifty day moving average price is $16.31 and its 200-day moving average price is $22.81.

Fulgent Genetics (NASDAQ:FLGT) last issued its earnings results on Friday, February 27th. The company reported $0.16 earnings per share for the quarter, topping analysts’ consensus estimates of $0.02 by $0.14. The business had revenue of $83.34 million during the quarter, compared to analyst estimates of $85.38 million. Fulgent Genetics had a negative return on equity of 2.22% and a negative net margin of 18.75%.Fulgent Genetics has set its FY 2026 guidance at -1.450–1.450 EPS. On average, sell-side analysts anticipate that Fulgent Genetics will post -2.48 earnings per share for the current year.

Hedge Funds Weigh In On Fulgent Genetics

A number of institutional investors and hedge funds have recently modified their holdings of FLGT. Federated Hermes Inc. increased its position in shares of Fulgent Genetics by 1.2% during the 4th quarter. Federated Hermes Inc. now owns 47,102 shares of the company’s stock valued at $1,237,000 after purchasing an additional 552 shares during the last quarter. Rhumbline Advisers boosted its holdings in shares of Fulgent Genetics by 2.4% in the second quarter. Rhumbline Advisers now owns 33,139 shares of the company’s stock worth $659,000 after buying an additional 785 shares during the last quarter. Swiss National Bank grew its position in Fulgent Genetics by 3.2% during the fourth quarter. Swiss National Bank now owns 39,200 shares of the company’s stock valued at $1,030,000 after buying an additional 1,200 shares during the period. Mackenzie Financial Corp increased its holdings in Fulgent Genetics by 11.2% during the third quarter. Mackenzie Financial Corp now owns 12,155 shares of the company’s stock valued at $275,000 after buying an additional 1,220 shares during the last quarter. Finally, Kestra Advisory Services LLC bought a new position in Fulgent Genetics in the fourth quarter worth approximately $35,000. 48.06% of the stock is currently owned by hedge funds and other institutional investors.

About Fulgent Genetics

Fulgent Genetics, Inc (NASDAQ: FLGT) is a California-based company specializing in high-complexity genetic testing and diagnostic services. Operating from its headquarters in Temple City, Fulgent leverages next-generation sequencing (NGS) technologies and advanced bioinformatics to deliver a broad range of clinical and research assays. The company’s infrastructure includes CAP- and CLIA-certified laboratories, enabling it to process large volumes of samples with rapid turnaround times.

Fulgent’s product portfolio encompasses hereditary cancer panels, rare disease and neuromuscular disorder testing, pharmacogenomic screenings, non-invasive prenatal tests, and infectious disease assays including COVID-19 diagnostics.